Literature DB >> 2868265

Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen.

A Thyss, G Milano, J Kubar, M Namer, M Schneider.   

Abstract

Co-administration of ketoprofen was found in 4 of 118 cycles of high-dose methotrexate (MTX) analysed retrospectively in thirty-six patients. All 4 cycles were characterised by severe MTX toxicity, which was fatal in three cases. Simultaneous administration of ketoprofen was associated with prolonged and striking enhancement of serum MTX levels. There were no abnormalities in MTX kinetics or evidence of MTX toxicity when ketoprofen was given at least 12 h after completion of high-dose MTX infusion. The kidney may be the site of drug interaction. This high-risk association between MTX toxicity and ketoprofen may also apply to other non-steroidal anti-inflammatory drugs.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2868265     DOI: 10.1016/s0140-6736(86)90786-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  43 in total

Review 1.  Pharmacology of anticancer drugs in the elderly population.

Authors:  Hans Wildiers; Martin S Highley; Ernst A de Bruijn; Allan T van Oosterom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Saturable pharmacokinetics in the renal excretion of drugs.

Authors:  C A van Ginneken; F G Russel
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

3.  Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for psoriatic arthropathy.

Authors:  P J Wallis; K S Ryatt; T J Constable
Journal:  Ann Rheum Dis       Date:  1989-03       Impact factor: 19.103

Review 4.  Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs.

Authors:  R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

Review 5.  Pharmacokinetic drug interactions of commonly used anticancer drugs.

Authors:  F M Balis
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

6.  Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.

Authors:  Kunihiro Suzuki; Kosuke Doki; Masato Homma; Hirofumi Tamaki; Satoko Hori; Hisakazu Ohtani; Yasufumi Sawada; Yukinao Kohda
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

7.  Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial.

Authors:  M Joerger; A D R Huitema; S Krähenbühl; J H M Schellens; T Cerny; M Reni; E Zucca; F Cavalli; A J M Ferreri
Journal:  Br J Cancer       Date:  2010-02-02       Impact factor: 7.640

Review 8.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics of drugs used in juvenile arthritis.

Authors:  K J Skeith; F Jamali
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

Review 10.  The problems and pitfalls of NSAID therapy in the elderly (Part II).

Authors:  A G Johnson; R O Day
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.